AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16623676 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased Kt/V (0.20 increase)
Number of subjects: 190
Study 16623676 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased calcium carbonate use (2 g/day)
Number of subjects: 190
Study 12767316 — intervention group
Group type: EXPERIMENTAL
Intervention: Flickering light stimulation at 100 mg/dl blood glucose
Number of subjects: 12
Study 12767316 — intervention group
Group type: EXPERIMENTAL
Intervention: Flickering light stimulation at 300 mg/dl blood glucose
Number of subjects: 12
Study 11203940 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide
Number of subjects: 25
Study 11203940 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide
Number of subjects: 25
Study 9180311 — intervention group
Group type: EXPERIMENTAL
Intervention: Regent Biogel Reveal gloves
Number of subjects: 0
Study 9180311 — intervention group
Group type: COMPARATOR
Intervention: Standard double-gloves
Number of subjects: 0
Study 1442596 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosages of diuretics
Number of subjects: 3600
Study 1442596 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dosages of diuretics
Number of subjects: 3600
Study 1442596 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-sparing antihypertensive regimens
Number of subjects: 3600
Study 3914582 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg lactate for 16 weeks
Number of subjects: 35
Study 3914582 — intervention group
Group type: COMPARATOR
Intervention: Placebo for the first 8 weeks, followed by Mg lactate for the next 8 weeks
Number of subjects: 35
Study 31407644 — intervention group
Group type: EXPERIMENTAL
Intervention: FCU Online with coaching support
Number of subjects: 322
Study 31407644 — intervention group
Group type: EXPERIMENTAL
Intervention: FCU Online
Number of subjects: 322
Study 31407644 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 322
Study 28967351 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD (100 µg)
Number of subjects: 18
Study 28967351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 27206947 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin (N)
Number of subjects: 591
Study 27206947 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin (E/S)
Number of subjects: 591
Study 27206947 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Ezetimibe/Simvastatin/Niacin (E/S/N)
Number of subjects: 591
Study 27206947 — intervention group
Group type: COMPARATOR
Intervention: Statins and low-fat diets (systematic review)
Number of subjects: 591
Study 27206947 — intervention group
Group type: COMPARATOR
Intervention: Lp(a)-lowering therapies (systematic review)
Number of subjects: 591
Study 25343656 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisional Balance Feedback (DBF)
Number of subjects: 724
Study 25343656 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback (PNF)
Number of subjects: 724
Study 25343656 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 724
Study 22160441 — intervention group
Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program (ISFP)
Number of subjects: 446
Study 22160441 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 446
Study 20482507 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 0
Study 18929475 — intervention group
Group type: EXPERIMENTAL
Intervention: Camphor-Crataegus berry extract combination (Korodin(®))
Number of subjects: 88
Study 18929475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 15977263 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine
Number of subjects: 500
Study 15977263 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 500
Study 11849200 — intervention group
Group type: EXPERIMENTAL
Intervention: First antihypertensive treatment
Number of subjects: 0
Study 11849200 — intervention group
Group type: EXPERIMENTAL
Intervention: Second antihypertensive treatment
Number of subjects: 0
Study 11849200 — intervention group
Group type: EXPERIMENTAL
Intervention: Third antihypertensive treatment
Number of subjects: 0
Study 11849200 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender influence on treatment willingness
Number of subjects: 0
Study 11849200 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-making difficulty influence
Number of subjects: 0
Study 11849200 — intervention group
Group type: EXPERIMENTAL
Intervention: Years in full-time education influence
Number of subjects: 0
Study 11081784 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (8 mg once daily, increased to 16 mg after 4 weeks)
Number of subjects: 268
Study 11081784 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg once daily, increased to 100 mg after 4 weeks)
Number of subjects: 268
Study 11081784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 8743615 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide at 0% concentration
Number of subjects: 11
Study 8743615 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 10% concentration
Number of subjects: 11
Study 8743615 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 20% concentration
Number of subjects: 11
Study 8743615 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 30% concentration
Number of subjects: 11
Study 8743615 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 40% concentration
Number of subjects: 11
Study 1527420 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 103-HgR
Number of subjects: 0
Study 3936081 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 5 mg
Number of subjects: 26
Study 3936081 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 25 mg
Number of subjects: 26
Study 3936081 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 50 mg
Number of subjects: 26
Study 30888034 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 120
Study 30888034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30355325 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture group (RAG)
Number of subjects: 0
Study 30355325 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture group (PAG)
Number of subjects: 0
Study 27369468 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax AWS‐S100 videolaryngoscope (AWS)
Number of subjects: 35
Study 27369468 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh (MAC) laryngoscope
Number of subjects: 35
Study 24909293 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 261
Study 24909293 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 261
Study 24909293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 24909293 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg and 10 mg
Number of subjects: 261
Study 24909293 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 261
Study 22750851 — intervention group
Group type: EXPERIMENTAL
Intervention: High Personal Standards condition
Number of subjects: 100
Study 22750851 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Personal Standards perfectionism and Evaluative Concerns perfectionism
Number of subjects: 100
Study 22750851 — intervention group
Group type: COMPARATOR
Intervention: Non-perfectionist condition
Number of subjects: 100
Study 22750851 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfectionist conditions (High Personal Standards and Combination of Personal Standards and Evaluative Concerns)
Number of subjects: 100
Study 20056736 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin intervention for three months
Number of subjects: 0
Study 20056736 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 18685047 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Checker socks (active treatment)
Number of subjects: 50
Study 18685047 — intervention group
Group type: COMPARATOR
Intervention: Placebo socks (control)
Number of subjects: 50
Study 15798477 — intervention group
Group type: EXPERIMENTAL
Intervention: Paragon CRT lenses
Number of subjects: 18
Study 15798477 — intervention group
Group type: COMPARATOR
Intervention: CIBA Vision Focus NIGHT and DAY lenses
Number of subjects: 18
Study 12844388 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Copper diet (0.7 mg Cu/d)
Number of subjects: 12
Study 12844388 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-Copper diet (1.6 mg Cu/d)
Number of subjects: 12
Study 12844388 — intervention group
Group type: COMPARATOR
Intervention: High-Copper diet (6.0 mg Cu/d)
Number of subjects: 12
Study 10231502 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony stimulating factor 200 microg
Number of subjects: 60
Study 10231502 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony stimulating factor 400 microg
Number of subjects: 60
Study 10231502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8916559 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS180048 25 mg
Number of subjects: 209
Study 8916559 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS180048 50 mg
Number of subjects: 209
Study 8916559 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS180048 75 mg
Number of subjects: 209
Study 8916559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 8916559 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS180048 (25 mg, 50 mg, 75 mg)
Number of subjects: 209
Study 29146865 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 221
Study 29146865 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 221
Study 29146865 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification (Control)
Number of subjects: 221
Study 26947523 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided group
Number of subjects: 1575
Study 26947523 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care group
Number of subjects: 1575
Study 25514686 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (group lyric analysis intervention)
Number of subjects: 131
Study 25514686 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal therapy (group talk therapy session)
Number of subjects: 131
Study 25514686 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (eventually received group recreational music therapy intervention)
Number of subjects: 131
Study 22183938 — intervention group
Group type: EXPERIMENTAL
Intervention: gMS‐Classifier1 (panel of four α‐glucose IgM antibodies)
Number of subjects: 258
Study 20637969 — intervention group
Group type: EXPERIMENTAL
Intervention: S/N + S4 (sumatriptan 4 mg SC after S/N 85/500 mg)
Number of subjects: 30
Study 20637969 — intervention group
Group type: EXPERIMENTAL
Intervention: S/N + S6 (sumatriptan 6 mg SC after S/N 85/500 mg)
Number of subjects: 30
Study 20637969 — intervention group
Group type: COMPARATOR
Intervention: S100 + S100 (sumatriptan 100 mg PO, 2 tablets administered 2 hours apart)
Number of subjects: 30
Study 17517804 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 10
Study 15747123 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal arteriolar narrowing (definition 1)
Number of subjects: 54
Study 15747123 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal arteriolar narrowing (definition 2)
Number of subjects: 54
Study 12587622 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 12
Study 12587622 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 12
Study 9469360 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cycles of bleomycin, etoposide, and cisplatin (BEP)
Number of subjects: 118
Study 9469360 — intervention group
Group type: COMPARATOR
Intervention: Four cycles of bleomycin, etoposide, and cisplatin (BEP)
Number of subjects: 118
Study 9469360 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum HCG > 1,000 mIU/mL
Number of subjects: 118
Study 9469360 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum HCG ≤ 1,000 mIU/mL
Number of subjects: 118
Study 8551469 — intervention group
Group type: COMPARATOR
Intervention: Fetal acoustic stimulation (FAS) using an electrolarynx device for 1-3 seconds before a second version attempt.
Number of subjects: 16
Study 2229465 — intervention group
Group type: EXPERIMENTAL
Intervention: flurazepam 30 mg
Number of subjects: 99
Study 2229465 — intervention group
Group type: EXPERIMENTAL
Intervention: flurazepam 15 mg
Number of subjects: 99
Study 2229465 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 15 mg
Number of subjects: 99
Study 2229465 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 99
Study 713432 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of lysine salt of acetylsalicylic acid
Number of subjects: 7
Study 713432 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of lysine salt of acetylsalicylic acid
Number of subjects: 7
Study 713432 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 7
Study 31586871 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific exercise programme (balance and jump exercises), performed 4 times per week
Number of subjects: 62
Study 31586871 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific exercise programme (balance and jump exercises), performed at least twice per week
Number of subjects: 62
Study 31586871 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific exercise programme)
Number of subjects: 62
Study 26142932 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 500,000 IU administered orally as 50,000 IU daily for 10 consecutive days
Number of subjects: 109
Study 26142932 — intervention group
Group type: COMPARATOR
Intervention: D2 600,000 IU single mega dose administered orally
Number of subjects: 109
Study 23874383 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary teaching intervention (n = 107 villages)
Number of subjects: 2364
Study 23874383 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional kits for girls (n = 54 villages)
Number of subjects: 2364
Study 23874383 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 107 villages)
Number of subjects: 2364
Study 20725058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Soothe/Sleep and Introduction of Solids)
Number of subjects: 160
Study 20725058 — intervention group
Group type: EXPERIMENTAL
Intervention: First intervention only (Soothe/Sleep)
Number of subjects: 160
Study 20725058 — intervention group
Group type: EXPERIMENTAL
Intervention: Second intervention only (Introduction of Solids)
Number of subjects: 160
Study 20725058 — intervention group
Group type: COMPARATOR
Intervention: Control group (no interventions)
Number of subjects: 160
Study 19514576 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Bipolar Femoral Head (ABFH)
Number of subjects: 73
Study 19514576 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 73
Study 19514576 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal Femoral Nail Anti-Rotation (PFNA)
Number of subjects: 73
Study 17002571 — intervention group
Group type: EXPERIMENTAL
Intervention: teriparatide 20 or 40 microg/day for a median of 19 months
Number of subjects: 1637
Study 17002571 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1637
Study 12737326 — intervention group
Group type: EXPERIMENTAL
Intervention: Reumacon (CPH82)
Number of subjects: 100
Study 12737326 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 100
Study 10671902 — intervention group
Group type: COMPARATOR
Intervention: Sparfloxacin 300 mg alone (Control)
Number of subjects: 8
Study 10671902 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1.5 g every 12 h for five doses, with the fifth dose concurrently with sparfloxacin 300 mg (Treatment B)
Number of subjects: 8
Study 10671902 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1.5 g every 12 h for five doses, with the fifth dose 2 h after sparfloxacin 300 mg (Treatment C)
Number of subjects: 8
Study 10671902 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1.5 g every 12 h for five doses, with the fifth dose 4 h after sparfloxacin 300 mg (Treatment D)
Number of subjects: 8
Study 9348562 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral UFT plus leucovorin
Number of subjects: 0
Study 8385216 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blockade condition using i.v. propranolol
Number of subjects: 37
Study 8385216 — intervention group
Group type: EXPERIMENTAL
Intervention: combined beta‐ and alpha‐blockade condition using both i.v. propranolol and i.v. phentolamine
Number of subjects: 37
Study 8385216 — intervention group
Group type: COMPARATOR
Intervention: saline placebo condition
Number of subjects: 37
Study 8385216 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐receptor blockade
Number of subjects: 37
Study 3535719 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin and piperacillin
Number of subjects: 118
Study 3535719 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin and piperacillin
Number of subjects: 118
Study 29211308 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine 60 mg/m2 on 5 consecutive days (5-day regimen)
Number of subjects: 103
Study 29211308 — intervention group
Group type: COMPARATOR
Intervention: Guadecitabine 90 mg/m2 on 5 consecutive days (5-day regimen)
Number of subjects: 103
Study 29211308 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine 60 mg/m2 on 10 consecutive days (10-day regimen)
Number of subjects: 103
Study 27255082 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids intervention
Number of subjects: 102
Study 27255082 — intervention group
Group type: COMPARATOR
Intervention: Control clusters
Number of subjects: 102
Study 25137863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous patient controlled analgesia (PCA) with fentanyl
Number of subjects: 34
Study 25137863 — intervention group
Group type: COMPARATOR
Intervention: Patient controlled epidural analgesia (PCEA) with Bupivacaine 0.125% plus 2 microgram per ml fentanyl
Number of subjects: 34
Study 25137863 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PCA and PCEA)
Number of subjects: 34
Study 22091534 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided aspiration and sclerotherapy with 1% polidocanol (10% of cyst volume)
Number of subjects: 40
Study 22091534 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic deroofing
Number of subjects: 40
Study 20733448 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation (1000 mg vitamin C and 400 IU vitamin E daily)
Number of subjects: 9968
Study 20733448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9968
Study 20733448 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation
Number of subjects: 9968
Study 18026149 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan (200 mg/m2) after cyclophosphamide (4 g/m2) for PBPC mobilization
Number of subjects: 80
Study 18026149 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy (paclitaxel and carboplatin)
Number of subjects: 80
Study 16221027 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples with infidelity (n = 19)
Number of subjects: 134
Study 16221027 — intervention group
Group type: EXPERIMENTAL
Intervention: Men who had participated in affairs
Number of subjects: 134
Study 16221027 — intervention group
Group type: COMPARATOR
Intervention: Couples without infidelity (n = 115)
Number of subjects: 134
Study 12383812 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% (Xalatan)
Number of subjects: 25
Study 12383812 — intervention group
Group type: COMPARATOR
Intervention: Unoprostone 0.15% (Rescula)
Number of subjects: 25
Study 10673876 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 15 mg kg‐1 (n = 21)
Number of subjects: 42
Study 10673876 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group, n = 21)
Number of subjects: 42
Study 8849185 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Youth Inform education programme
Number of subjects: 1000
Study 2181119 — intervention group
Group type: EXPERIMENTAL
Intervention: ticarcillin/clavulanate, 3.1 g every six hours until clinical signs resolved
Number of subjects: 27
Study 2181119 — intervention group
Group type: COMPARATOR
Intervention: cefoxitin, 2 g every six hours until clinical signs resolved
Number of subjects: 27
Study 2181119 — intervention group
Group type: EXPERIMENTAL
Intervention: ticarcillin/clavulanate
Number of subjects: 27
Study 2181119 — intervention group
Group type: COMPARATOR
Intervention: cefoxitin
Number of subjects: 27
Study 7008891 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (1000 mg/day)
Number of subjects: 5
Study 31749128 — intervention group
Group type: COMPARATOR
Intervention: AB-kefir (Bifidobacterium longum, Lactobacillus acidophilus, L. fermentum, L. helveticus, L. paracasei, L. rhamnosus, and Streptococcus thermophiles; total 10 log CFU/sachet) daily for 3 weeks
Number of subjects: 56
Study 31749128 — intervention group
Group type: COMPARATOR
Intervention: AB-kefir
Number of subjects: 56
Study 31619610 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Dewaxed Brown Rice (DBR) ingestion
Number of subjects: 0
Study 31619610 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31287522 — intervention group
Group type: EXPERIMENTAL
Intervention: POEM (n=67)
Number of subjects: 133
Study 31287522 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic dilation (n=66)
Number of subjects: 133
Study 31287522 — intervention group
Group type: EXPERIMENTAL
Intervention: POEM
Number of subjects: 133
Study 31287522 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic dilation
Number of subjects: 133